Target Information

Toopi Organics, founded in 2019 near Bordeaux by Michael Roes, is an innovative biotechnology startup based in France. The company specializes in the collection and conversion of human urine into microbial plant biostimulants intended for agricultural applications. This pioneering approach seeks to re-value human urine as a natural resource, addressing both agricultural sustainability and water conservation, especially pertinent amid global water scarcity.

Under the leadership of Roes, Toopi Organics has successfully established a unique urine collection network throughout France. The firm has also received market approvals for its groundbreaking biostimulant in six EU member states, marking it as a first-in-class product in the microbial biostimulant segment derived from the fermentation of human urine.

Industry Overview

The sustainable agriculture sector in France is rapidly evolving, influenced by escalating environmental challenges and the necessity for innovative agricultural solutions. Increasing concerns regarding climate change, particularly with the prevalence of droughts and water restrictions, have elevated the importance of sustainability within the industry. Farmers are now seeking alternative resources and practices to optimize water use and improve soil health.

Furthermore, the global agricultural landscape has faced significant disruptions due to geopolitical tensions, notably the war in Ukraine, which triggered unprecedented fertilizer shortages coupled with soaring prices. This crisis has underscored the need to explore sustainable sources for fertilizers, thereby boosting interest in biotechnology solutions that can mitigate these issues.

France's regulatory framework increasingly supports sustainable practices and innovations within agriculture. The government incentivizes startups that focus on green technologies, thereby boosting investment in the sector. As a result, startups like Toopi Organics are well-positioned to capitalize on this momentum to address critical issues facing the agricultural industry.

The Rationale Behind the Deal

Seeking to further its mission, Toopi Organics has secured €16 million in its Series A funding round, led by VisVires New Protein along with several impact funds and Banque BNP Paribas Développement. This round primarily aims to reinforce the company’s urine collection network and enhance production capabilities. The fundraising is critical for the company as it aims for significant growth, targeting the utilization of 600,000 hectares by 2027, equating to the transformation of 2 million liters of human urine—all while contributing to substantial water savings.

Investor Information

VisVires New Protein leads the investment in Toopi Organics, demonstrating a commitment to supporting sustainable innovations in the agriculture sector. The involvement of other impact funds such as Edaphon, Noshaq, MAIF Impact, and existing investors like IRDI, JOHES, and MakeSense signifies strong confidence in the company's potential and strategic growth trajectory. These investors focus on socially responsible initiatives, indicating that Toopi Organics aligns well with their mission of fostering impactful and sustainable business models.

View of Dealert

This investment in Toopi Organics represents a compelling opportunity in the growing sustainability sector. Given the firm’s innovative approach and the increasing demand for sustainable agricultural solutions, the deal is poised to yield significant returns in the long term. The company’s unique value proposition of transforming human urine into biostimulants not only addresses urgent ecological needs but also enhances food security by mitigating fertilizer scarcity.

Additionally, Toopi Organics’ established network and regulatory approvals across multiple EU states position it favorably against competitors, facilitating its potential growth acceleration. The favorable alignment with wider environmental and agricultural trends suggests that this investment could lead to substantial market impact and value creation.

Overall, the sustainability sector is increasingly recognized for its long-term viability and profitability. As environmental concerns intensify, companies like Toopi Organics that offer innovative solutions will likely see continued interest from investors, making this deal a promising initiative for future advancements in agricultural sustainability.

View Original Article

Similar Deals

Novo Holdings A/S Coave Therapeutics

2025

Series A Biotechnology & Medical Research France
Redmile Group One Biosciences

2025

Series A Biotechnology & Medical Research France
Jeito Capital ReproNovo

2025

Series A Biotechnology & Medical Research France
Jeito Capital Callio Therapeutics

2025

Series A Biotechnology & Medical Research France
Novo Holdings A/S and Bpifrance Coave Therapeutics

2025

Series A Biotechnology & Medical Research France
AMBA XENOTHERA

2023

Series A Biotechnology & Medical Research France
OrbiMed and Jeito Capital Corteria Pharmaceuticals

2023

Series A Biotechnology & Medical Research France
Alizé Pharma 3 Alizé Pharma 3

2023

Series A Biotechnology & Medical Research France

VisVires New Protein

invested in

Toopi Organics

in 2023

in a Series A deal

Disclosed details

Transaction Size: $16M

Equity Value: $11M

Deal Parametres
Industry
Country
Seller type

Sign Up to Dealert